Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Certara Announces Completion of Acquisition of Simcyp Limited
March 13, 2012
Acquisition of Simcyp adds important predictive science methodologies to Certara’s translational science approach to drug development.
ST. LOUIS, MO –March 13, 2012 – Certara™, a Vector Capital portfolio company and a leading provider of drug discovery and development software and scientific consulting services, today announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp is a leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, including pediatric populations. The now completed acquisition means Simcyp’s highly-regarded technologies will be integrated into planned Certara translational science initiatives.
Certara was formed as the outgrowth of Vector Capital’s acquisition of Tripos, and Pharsight, both leading drug development industry companies. Through Certara, Vector Capital is methodically fulfilling its commitment and vision of building an organization focused on translational science approaches to drug development. Confirming the completion of the Simcyp acquisition, Certara’s President and Chief Executive Officer, Jim Hopkins, said, “This acquisition enables Simcyp to continue its focus on its core business competencies, and helps Certara in moving the drug discovery and development industry a giant step forward in integrating technologies, workflows and processes previously hampered by organizational silos, and discrete research activities.”
John Evans, Managing Director at Simcyp, said, “This is an exciting time for us. We are joining an organization that shares our vision of improving human health. Certara’s robust product and services offering, coupled with Vector Capital’s global capabilities, industry knowledge, and financial resources make this an ideal environment for success.”
About Certara
Certara™ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery, with Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development. Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation and scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com.
About Simcyp
As a Certara portfolio company, Simcyp will continue to provide platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog and mouse). The technology allows pharmaceutical researchers to predict in vivo outcomes from routinely generated in vitro data, to fit Simcyp models to observed clinical data, and to assess inter-individual variability through ‘real-life’ simulations. This informs decision-making in drug development. Simcyp will also continue providing expert consultancy services, run educational workshops, and support academic and drug regulatory research through the provision of not-for-profit simulator licenses. For further information please visit www.simcyp.com.
About Vector Capital
With over $2 billion of capital, Vector Capital is a leading global private equity firm specializing in spinouts, buyouts and recapitalizations of established technology businesses. Vector identifies and pursues these complex investments in both the private and public markets. Vector actively partners with management teams to devise and execute new financial and business strategies that materially improve the competitive standing of these businesses and enhance their value for employees, customers and shareholders. Among Vector's notable investments are Aladdin Knowledge Systems, Cambium Networks, Certara, Corel, Gerber Scientific, LANDesk, Precise Software Solutions, Printronix, RAE Systems, Register.com, SafeNet, Savi Technology, Trafficmaster, WatchGuard Technologies, and WinZip. For more information, visit www.vectorcapital.com .
Contact
Certara
Diana O’Rourke, 314-951-3310
Director of Software Marketing
diana.orourke@certara.com